Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRadimed Corporation (IRMD) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents provide structured detail on financial performance, governance, and material events related to iRadimed’s business of MRI-compatible medical devices, including non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems.
Among the key filings are Form 8-K current reports, which iRadimed uses to announce events such as quarterly financial results, changes in its Board of Directors, and outcomes of stockholder meetings. For example, Form 8-K filings have reported record quarterly revenue, the use of non-GAAP financial measures like non-GAAP net income and free cash flow, the completion of a new facility in Orlando, Florida, and the retirement and appointment of directors. Other 8-Ks furnish press releases that detail FDA 510(k) clearance for the MRidium 3870 IV Infusion Pump System and summarize voting results from the Annual Meeting of Stockholders.
Filings also disclose listing information for iRadimed’s common stock, including its trading symbol IRMD and its listing on the NASDAQ Global Market, with one filing referencing the NASDAQ Capital Market. Governance-related sections describe board committee assignments, independence determinations, and advisory votes on executive compensation. These documents collectively give insight into how the company is overseen and how major decisions are communicated to investors.
On Stock Titan, iRadimed’s SEC filings are paired with AI-powered summaries that explain the contents of lengthy documents in plain language. Users can quickly see the main points of quarterly earnings announcements, board changes, and stockholder votes without reading every page. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while AI-generated highlights help readers identify sections related to financial condition, risk factors, and corporate actions. For those researching IRMD’s regulatory history and ongoing obligations, this page offers a focused view of its official SEC reporting.
IRADIMED CORP insider Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of common stock on April 20–21, 2026. Reported sale prices include $93.90, $93.14, $92.66, $91.65, $90.60 and $89.73 per share.
The filing notes these transactions were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. Post‑transaction line items show the trusts continuing to hold sizable indirect positions, with balances ranging from hundreds of thousands to over two million shares.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of 7,500 shares of common stock on April 13–14, 2026. The transactions were executed by the Phillip Susi 2008 Dynasty Trust at weighted average prices around $92–$94 per share under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, the Phillip Susi 2008 Dynasty Trust held 2,210,000 shares indirectly, while separate indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust as of April 13, 2026.
IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7. Reported sale prices ranged from $94.36 to $96.78 per share, and the filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following these sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, and states that Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock. The Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of IRMD on March 30, 2026 in three transactions at weighted average prices of $94.81, $95.66 and $96.53 per share. After these trades, the Dynasty Trust holds 2,225,000 shares, while additional indirect holdings reported include 162,950 shares in the Roger E. Susi Revocable Trust and 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan, and the reporting person disclaims beneficial ownership of the securities beyond his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported open-market sales of 7,500 shares of Common Stock, executed indirectly through the Phillip Susi 2008 Dynasty Trust. The sales occurred on March 23–24, 2026 at prices around $100 per share, including transactions at $99.58, $100.03, $100.71, $100.70 and $102.02 per share.
A footnote states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a scheduled selling program rather than ad hoc market timing. After the transactions, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares, while other indirect holdings included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust as of March 23, 2026. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported planned insider sales of company stock through a family trust. A total of 7,500 shares of common stock were sold on March 6, 2026 by the Phillip Susi 2008 Dynasty Trust in open-market transactions at weighted average prices of $98.25 and $99.12 per share, under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, indirect holdings reported for related trusts included 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust.
Iradimed Corporation (IRMD): Phillip Susi 2008 Dynasty Trust reported an intent to sell 2,362,500 shares of common stock, with the trust named as the selling holder. The excerpt also lists eight recent dispositions of 5,000 shares each on 12/08/2025, 12/15/2025, 12/22/2025, 12/29/2025, 01/05/2026, 01/12/2026, 01/20/2026, and 01/26/2026, showing proceeds for each sale.
IRadimed Corporation files its annual report describing a focused business developing MRI-compatible IV infusion pumps, patient vital-sign monitors and ferromagnetic detection devices used in hospital MRI environments.
For fiscal 2025, revenue was $83.8 million and income from operations was $26.1 million, an operating margin of about 31.2%. The company sells primarily through a U.S. direct sales force and international distributors, with the United States contributing 84% of revenue and devices accounting for 72% of revenue. Management highlights its new MRidium 3870 IV pump, 3880 monitor, and FMD1 detector, notes reliance on key suppliers, extensive FDA and international regulation, and outlines detailed risk factors, including product concentration, cybersecurity, competition, and supply-chain disruption.